Detection of Bladder Cancer Using a Point-of-Care Proteomic Assay

Urinary Survivin mRNA Expression and Urinary Nuclear Matrix Protein 22 BladderChek® and Urine Cytology in the Detection of Transitional Cell Carcinoma of the Bladder

“…The sensitivity of the NMP22BC test (77.5%) surpassed that of UC (46.3%) and the specificity of the NMP22BC test was 88.8% compared to 97.9% for UC [6]. The results of our study are in agreement with reported ranges [1,6]. Many studies reported the high sensitivity and specificity of urinary survivin mRNA in the early detection of bladder cancer by real-time RT-PCR [7,8].…”

The value of the NMP22 test for superficial bladder cancer diagnosis and follow-up

“…In their study, 79 of a total of 1331 patients (5.9%) bladder cancer was detected, however in our study, detection rate was higher (37.9%) in Group 1. This rate is relatively higher when compared with the study results published by Grossman et al [8] Our higher rates were attributed to inclusion of patients in our study with only benign pathology. In our study, our cytology results were comparable to the study results published by Grossman et al [8] , while sensitivity of our NMP22 test results was relatively higher.…”

“…This rate is relatively higher when compared with the study results published by Grossman et al [8] Our higher rates were attributed to inclusion of patients in our study with only benign pathology. In our study, our cytology results were comparable to the study results published by Grossman et al [8] , while sensitivity of our NMP22 test results was relatively higher. However, in our study, likelihood ratio of a positive test result was 7.36 for cytology, and 3.42 for NMP22 test which indicates that positive NMP22 test has a lower diagnostic accuracy when compared with the cytology.…”

Current and Emerging Bladder Cancer Urinary Biomarkers

“…Grossman et al evaluated NMP22 in comparison to cytology in the detection of bladder cancer in 1331 patients at risk for bladder cancer. This study demonstrated a sensitivity of NMP22 for bladder cancer detection of 55.7% (95% CI, 44.1-66.7%) and a specificity of 85.7% (95% CI, 83-87.6%) compared to 15.8% sensitivity and 99.2% specificity for urinary cytology [20]. Similar results were identified in a subsequent study evaluating NMP22 in the diagnosis of bladder cancer recurrence.…”